Literature DB >> 15763222

Hendra and Nipah viruses: new zoonotically-acquired human pathogens.

Joseph G McCormack1.   

Abstract

Some of the key features of Hendra and Nipah viruses are summarized in Table 1. The appearance of these new viruses over the last 10 years emphasizes a number of issues. (1) Epidemics of human infectious diseases can occur unexpectedly and with high impact in terms of morbidity and mortality. (2) We do not know what epidemiologic factors conspire to allow these viruses to stray out of their bat reservoirs into the two different intermediate hosts (horses and pigs) and then into humans. (3) We do not know how long these viruses have been present in the bat population, where they originated from, or if they are present in other parts of the world. (4)There may be other viruses waiting for similar opportunities to cross species.(5) It is unlikely that we have seen the last of these and related viruses.

Entities:  

Mesh:

Year:  2005        PMID: 15763222     DOI: 10.1016/j.rcc.2004.10.006

Source DB:  PubMed          Journal:  Respir Care Clin N Am        ISSN: 1078-5337


  3 in total

Review 1.  Ephrin-B2 and ephrin-B3 as functional henipavirus receptors.

Authors:  Kai Xu; Christopher C Broder; Dimitar B Nikolov
Journal:  Semin Cell Dev Biol       Date:  2011-12-30       Impact factor: 7.727

Review 2.  Nipah virus: epidemiology, pathology, immunobiology and advances in diagnosis, vaccine designing and control strategies - a comprehensive review.

Authors:  Raj Kumar Singh; Kuldeep Dhama; Sandip Chakraborty; Ruchi Tiwari; Senthilkumar Natesan; Rekha Khandia; Ashok Munjal; Kranti Suresh Vora; Shyma K Latheef; Kumaragurubaran Karthik; Yashpal Singh Malik; Rajendra Singh; Wanpen Chaicumpa; Devendra T Mourya
Journal:  Vet Q       Date:  2019-12       Impact factor: 3.320

3.  ANP32B is a nuclear target of henipavirus M proteins.

Authors:  Anja Bauer; Sebastian Neumann; Axel Karger; Ann-Kristin Henning; Andrea Maisner; Boris Lamp; Erik Dietzel; Linda Kwasnitschka; Anne Balkema-Buschmann; Günther M Keil; Stefan Finke
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.